193 related articles for article (PubMed ID: 10995902)
1. Induction therapy for clinical intestinal transplantation: comparison of four different regimens.
Pinna AD; Weppler D; Nery JR; Khan F; Ruiz P; Kato T; De Faria W; Berho M; Tzakis AG
Transplant Proc; 2000 Sep; 32(6):1193-4. PubMed ID: 10995902
[No Abstract] [Full Text] [Related]
2. The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival.
Bond G; Reyes J; Mazariegos G; Wu T; Schaefer N; Demetris J; Fung JJ; Starzl TE; Abu-Elmagd K
Transplant Proc; 2000 Sep; 32(6):1197-8. PubMed ID: 10995904
[No Abstract] [Full Text] [Related]
3. New immunosuppressive regimens in clinical intestinal transplantation.
Tzakis AG; Nery JR; Thompson J; Webb MG; Khan FA; Khan RT; Luque CD; Weppler D; Koutouby R; Romero R; Dowdy L; Reddy KR; Raskin J; Viciana A; Ruiz P; Byers P; Rogers A; Miller J; Ricordi C
Transplant Proc; 1997; 29(1-2):683-5. PubMed ID: 9123479
[No Abstract] [Full Text] [Related]
4. Mycophenolate mofetil as primary and rescue therapy in intestinal transplantation.
Tzakis AG; Weppler D; Khan MF; Koutouby R; Romero R; Viciana AL; Raskin J; Nery JR; Thompson J
Transplant Proc; 1998 Sep; 30(6):2677-9. PubMed ID: 9745545
[No Abstract] [Full Text] [Related]
5. Can antibody prophylaxis allow sparing of other immunosuppressives?
Vincenti F; Grinyo J; Ramos E; Nashan B; Stuart F; Kuypers D; Brattstrom C; Cho S; Ekberg H; Johnson R
Transplant Proc; 1999; 31(1-2):1246-8. PubMed ID: 10083557
[No Abstract] [Full Text] [Related]
6. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
[No Abstract] [Full Text] [Related]
7. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab.
Chin C; Pittson S; Luikart H; Bernstein D; Robbins R; Reitz B; Oyer P; Valantine H
Transplantation; 2005 Aug; 80(4):477-81. PubMed ID: 16123721
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Spasovski G; Sikole A; Paneva-Masin J
Transplant Proc; 2001; 33(7-8):3203-4. PubMed ID: 11750374
[No Abstract] [Full Text] [Related]
9. The efficacy of daclizumab for intestinal transplantation: preliminary report.
Abu-Elmagd K; Fung J; McGhee W; Martin D; Mazariegos G; Schaefer N; Demetris J; Starzl TE; Reyes J
Transplant Proc; 2000 Sep; 32(6):1195-6. PubMed ID: 10995903
[No Abstract] [Full Text] [Related]
10. Intestinal transplantation in children: a summary of clinical outcomes and prognostic factors in 108 patients from a single center.
Kato T; Gaynor JJ; Selvaggi G; Mittal N; Thompson J; McLaughlin GE; Nishida S; Moon J; Levi D; Madariaga J; Ruiz P; Tzakis A
J Gastrointest Surg; 2005 Jan; 9(1):75-89; discussion 89. PubMed ID: 15623448
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
[No Abstract] [Full Text] [Related]
12. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
[TBL] [Abstract][Full Text] [Related]
13. Experience with intestinal transplantation at the University of Miami.
Tzakis A; Webb M; Nery J; Rogers A; Koutouby R; Ruiz P; Karatzas T; Thompson J; Ricordi C
Transplant Proc; 1996 Oct; 28(5):2748-9. PubMed ID: 8908037
[No Abstract] [Full Text] [Related]
14. Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis.
Sellers MT; McGuire BM; Haustein SV; Bynon JS; Hunt SL; Eckhoff DE
Transplantation; 2004 Oct; 78(8):1212-7. PubMed ID: 15502722
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab as induction therapy in kidney and simultaneous pancreas-kidney transplantation.
Ciancio G; Mattiazzi A; Miller J; Burke GW
Minerva Urol Nefrol; 2003 Mar; 55(1):43-56. PubMed ID: 12773966
[TBL] [Abstract][Full Text] [Related]
16. Isolated intestinal versus composite visceral allografts: causes of graft failure.
de Vera ME; Reyes J; Demetris J; Mazariegos G; Schaefer N; Vargas H; Bond G; Wu T; Fung J; Starzl TE; Abu-Elmagd K
Transplant Proc; 2000 Sep; 32(6):1221-2. PubMed ID: 10995919
[No Abstract] [Full Text] [Related]
17. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
Innocenti F; Humeres R; Zamboni M; Sanhueza E; Zapata R; Hepp J; Rius M
Transplant Proc; 2003 Nov; 35(7):2520-1. PubMed ID: 14612001
[TBL] [Abstract][Full Text] [Related]
18. Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients.
Lácha J; Símová M; Nosková L; Teplan V; Vítko S
Transplant Proc; 2001 May; 33(3):2273-4. PubMed ID: 11377526
[No Abstract] [Full Text] [Related]
19. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization.
Smith JM; Nemeth TL; McDonald RA
Pediatr Transplant; 2004 Oct; 8(5):445-53. PubMed ID: 15367279
[TBL] [Abstract][Full Text] [Related]
20. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.
Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber AO
Transplant Proc; 2001; 33(1-2):1701-3. PubMed ID: 11267477
[No Abstract] [Full Text] [Related]
[Next] [New Search]
